Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1128442

	registered interest
	date	23/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish the evidence (a) his Department and (b) the Department for International Trade holds on growing a market for prescribed medicinal cannabis.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	257706
	answer	answer is ministerial correction date of answer 10/06/2019 answer text <p><ins class="ministerial"> <p><ins class="ministerial">The Department for International Trade and the Department of Health and Social Care are not specifically collecting data on the growth of the market for cannabis based products for medicinal use in the United Kingdom.</ins></p><p><ins class="ministerial">However, data from the Medicines and Healthcare products Regulatory Agency (MHRA) shows growing numbers of import notifications for medicinal cannabis and the Home Office has received increased numbers of licence applications.</ins></p><p><ins class="ministerial">In addition, UK companies exporting these products and foreign companies looking to invest in the UK have full access to government support, where they have the necessary authorisations from the MHRA and Home Office and a relevant Export Licence.</ins></p></ins></p><p><del class="ministerial">An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</del></p><p><del class="ministerial"><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></del></p><p><del class="ministerial">This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</del></p><p><del class="ministerial">In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</del></p><p><del class="ministerial"><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></del></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/06/2019 13:18:03 question first ministerially corrected 11/06/2019 11:31:21 answering member 4455 label Biography information for Seema Kennedy previous answer version 121340 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1129191

	registered interest
	date	03/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many prescriptions of (a) individual benzodiazepine drugs and (b) individual antidepressants were dispensed in the community in 2018.
	tabling member constituency	Bristol North West
	tabling member printed	Darren Jones
	uin	259400
	answer	answer is ministerial correction date of answer 11/06/2019 answer text <p>Information on the number of prescription items from the Prescription Cost Analysis system for benzodiazepines and antidepressants written in the United Kingdom and dispensed in the community in England, for the year 2018 can be found in the attached tables.</p><p>The data available is at prescription item level by presentation. Prescriptions are prescribed either by a paper prescription form or via an Electronic Prescription Service message. Each single item written on the form is counted as a prescription item. No information is available for those prescriptions written but not dispensed.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/06/2019 16:51:00 question first ministerially corrected 12/06/2019 14:34:05 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name PQ259400 table formatted.docx title Prescription data benzodiazipines & antidepressant previous answer version 122124 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4621 label Biography information for Darren Jones

1132035

	registered interest
	date	13/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Primary Care Networks
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the requirements for primary care networks to engage with the local community will be.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	264406
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p><ins class="ministerial"> <p><ins class="ministerial">Primary Care Networks (PCNs) are a new way for primary and community service organisations to work together. For PCNs to be successful they will need to work in partnership with local people and the communities they serve. Legal duties which currently apply to NHS service providers - including general practitioner practices - and commissioners around engagement and consultation will continue to be valid for PCNs.</ins></p></ins></p><p><del class="ministerial">NHS England and NHS Improvement, together with the National Institute for Health and Care Excellence, is developing a ’commercial framework’ setting out the parameters for the commercial approach for medicines in the health service in England.</del></p><p><del class="ministerial">The commercial framework will support a single, transparent, robust and integrated pricing and market access process, and is being tested with and informed through consultation with stakeholders including the Association of the British Pharmaceutical Industry.</del></p><p><del class="ministerial">In preparation for public consultation in the coming months, NHS England is actively engaging with industry trade bodies and health system partners, in the first instance, to outline progress on the development of the commercial framework. The consultation on the draft framework is anticipated to be launched in Quarter 3 2019 with consultation events to be held in Manchester and London, and implementation of the commercial framework is expected to follow.</del></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 18/06/2019 16:34:05 question first ministerially corrected 19/06/2019 08:36:30 answering member 4455 label Biography information for Seema Kennedy previous answer version 123829 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1125248

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ovarian Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) improve early diagnosis of ovarian cancer and (b) reduce the level of variation in diagnosis times between clinical commissioning groups.
	tabling member constituency	North East Derbyshire
	tabling member printed	Lee Rowley
	uin	252008
	answer	answer is ministerial correction date of answer 17/05/2019 answer text <p>The NHS Cancer Programme is committed to improving early diagnosis as outlined in the Long Term Plan ambition to diagnose three-quarters of all cancers at stages 1 and 2 by 2028. This includes all stageable cancers.</p><p>To achieve this ambition, the NHS Cancer Programme is working on a number of programmes to improve early diagnosis rates for all cancers. The Rapid Diagnostic Centres (RDCs) are a new flagship policy in the Long Term Plan that offer patients a range of tests in the same day with rapid access to results. These RDCs starting to be rolled out in 2019/20 and will support the overall early diagnosis ambition. The RDCs will upgrade and bring together the latest diagnostic equipment and expertise, building on 10 models piloted with Cancer Research UK, which have focused on diagnosing cancers where patients often present with non-specific symptoms, often the case with ovarian cancer, and may go to their general practitioner many times before being sent for tests, such as blood and stomach cancers.</p><p> </p><p>A new cancer diagnosis standard, designed to ensure that patients find out within 28 days if they have cancer, will be introduced in 2020. All hospitals in England are now collecting data on how long it takes patients to reach cancer diagnosis, and they are working to improve performance over the next year and reduce unwarranted variation, for example geographical variation.</p><p> </p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/05/2019 13:11:39 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4652 label Biography information for Lee Rowley

1125272

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Strokes: Death
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many deaths caused by stroke there were in affected areas in England during the pollution episode in April 2019; and what comparative assessment he has made of the number of deaths attributed to stroke in that period with the (a) expected average and (b) average over the last five years.
	tabling member constituency	Hammersmith
	tabling member printed	Andy Slaughter
	uin	251938
	answer	answer is ministerial correction date of answer 17/05/2019 answer text <p>According to the Daily Air Quality Index there were ‘moderate’ to ‘very high’ levels of air pollution in some areas of the United Kingdom between 7 and 8 April and between 15 to 25 April 2019. The figures for deaths caused by stroke in this period are not available in the requested format and a comparative assessment has not been made.</p><p>In January 2019, the Government launched the Clean Air Strategy, which sets out plans for dealing with all sources of air pollution to save lives, protect nature and boost the economy.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/05/2019 13:24:45 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1516 label Biography information for Andy Slaughter

1125273

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Heart Diseases: Death
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many deaths were caused by coronary heart disease in affected areas in England during the pollution episode in April 2019; and what comparative assessment he has made of the number of deaths attributed to heart disease in that period with the (a) expected average and (b) average over the last five years.
	tabling member constituency	Hammersmith
	tabling member printed	Andy Slaughter
	uin	251939
	answer	answer is ministerial correction date of answer 17/05/2019 answer text <p>According to the Daily Air Quality Index, there were ‘moderate’ to ‘very high’ levels of air pollution in some areas of the United Kingdom between 7 and 8 April 2019 and between 15 and 25 April 2019. The figures for deaths caused by coronary heart disease in this period are not available in the requested format and a comparative assessment has not been made.</p><p>In January 2019, the Government launched the Clean Air Strategy, which sets out plans for dealing with all sources of air pollution to save lives, protect nature and boost the economy.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/05/2019 13:22:33 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1516 label Biography information for Andy Slaughter

1125320

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asthma: Prescriptions
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect of asthma prescription charges on lifelong asthma sufferers.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	uin	251955
	answer	answer is ministerial correction date of answer 17/05/2019 answer text <p>The Department has made no such assessment.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/05/2019 12:34:53 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1447 label Biography information for Andrew Rosindell

1125336

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescriptions: Fees and Charges
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to review which long-term health conditions should be exempt from NHS prescription charges.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	252045
	answer	answer is ministerial correction date of answer 17/05/2019 answer text <p>The Department has no current plans to review or amend the list of medical conditions that provide exemption from prescription charges. Extensive arrangements are already in place to help people afford National Health Service prescriptions. These include a broad range of NHS prescription charge exemptions.</p><p>To support those with greatest need who do not qualify for an exemption, prescription prepayment certificates are available. A holder of a 12-month certificate can get all the prescriptions they need for just £2 per week.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/05/2019 13:13:17 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4523 label Biography information for Catherine West

1125364

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ocrelizumab
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress he has made on the (a) negotiations for NHS access to and (b) appraisal of Ocrelizumab as a treatment for primary progressive MS.
	tabling member constituency	South Cambridgeshire
	tabling member printed	Heidi Allen
	uin	252055
	answer	answer is ministerial correction date of answer 17/05/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent an effective use of NHS resources.</p><p>NICE is currently developing technology appraisal guidance on the use of ocrelizumab for treating primary progressive multiple sclerosis, with final guidance expected in June 2019. NHS England and Roche have now reached a commercial agreement and on 9 May NICE published final draft guidance which recommended ocrelizumab within its marketing authorisation, as an option for treating early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults. Ocrelizumab will now be routinely available for eligible adults.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/05/2019 12:35:52 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4516 label Biography information for Heidi Allen

1125394

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmaceutical Price Regulation Scheme
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much money was accrued to the public purse under the pharmaceutical price regulation scheme and (b) what proportion of that money was allocated to clinical commissioning groups between 2014 and 2019.
	tabling member constituency	Rotherham
	tabling member printed	Sarah Champion
	uin	252068
	answer	answer is ministerial correction date of answer 17/05/2019 answer text <p>Under the 2014 Pharmaceutical Price Regulation Scheme (PPRS), scheme members made payments to the Department. The 2014 PPRS has now delivered over £2.7 billion of PPRS payments. The following table shows the annual aggregate PPRS payments from 2014 until the end of the PPRS in December 2018. The 2019 Voluntary Scheme for Branded Medicines Pricing and Access is the current voluntary scheme.</p><table><tbody><tr><td><p>Period</p></td><td><p>Aggregate PPRS payments</p></td></tr><tr><td><p>2014</p></td><td><p>£311 million</p></td></tr><tr><td><p>2015</p></td><td><p>£847 million</p></td></tr><tr><td><p>2016</p></td><td><p>£628 million</p></td></tr><tr><td><p>2017</p></td><td><p>£387 million</p></td></tr><tr><td><p>2018</p></td><td><p>£615 million</p></td></tr></tbody></table><p> </p><p>Further aggregate net sales and payment information can be found at the following link:</p><p><a href="https://www.gov.uk/government/collections/pprs-quarterly-net-sales-and-payment-information" target="_blank">https://www.gov.uk/government/collections/pprs-quarterly-net-sales-and-payment-information</a></p><p>Each year, the Department estimates the England share of expected income from the PPRS which is then included within NHS England baseline financial allocations. Decisions on how to allocate funding across the health system is for NHS England to determine, in line with patient need.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/05/2019 12:39:55 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4267 label Biography information for Sarah Champion